Bevacizumab (Avastin®) is a humanized monoclonal antibody against vascular endothelial growth factor (VEGF) used to inhibit VEGF function and, as a result, inhibit tumor angiogenesis (1). This evidence concerns the gene VEGFA and neoplasm.